Introduction
CD33 is a transmembrane protein of the Siglec family [1] . Siglecs bind to SIAs and are expressed by Hematopoietic Stem Cells (HSCs) which are present in Umbilical Cord Blood (UCB) cells. Humans express a larger family of CD33 related siglecs. Innate response is the body's first line of defense, but it can also result in damage to host over time. Siglecs act as a negative regulator in immune cells like monocytes and macrophages to minimize damage [2] . This interaction is essential in balancing the signals in a cell to bring about homeostasis. The bestknown Siglecs are CD22 and CD33. Over the last two decades, many more Siglecs have been identified. Siglecs play a role in the regulation of immune systems by binding to SIAs. Humans express a larger family of CD33 related siglecs and can be present on the same cells, e.g., monocytes express siglec-3, 5, 7, 9 and 10. Siglecs can carry out immunological functions that could be positive or negative. For e.g., creating a barrier against pathogens thus reducing interactions and at the same time weakening complement activation [3, 4] .
CD33 is a critical molecule in the inflammatory response, depending on the SIA microenvironment for its repressor activity. Reduced CD33 leads to an increase in inflammatory cytokines, such as IL-1b, TNF-α, and IL-8. Hyperglycemia down-regulates CD33 expression and triggers the spontaneous secretion of TNF-α by peripheral monocytes and increased free radical generation. CD33 thus has a vital role in the pathology of with type 2 diabetes [5, 6] . SIA occupies the terminal end in glycan molecules on the surfaces of cells. Pathogenic bacteria have evolved to cover themselves in SIA that allows them to circumvent the host's innate immune response, or they can use it as a nutrient. 
Sialic acid synthesized by pathogens

Pathogen Diseases
Neisseria meningitides B Meningitis
Escherichia coli K1 Neonatal Meningitis
Group B Streptococcus Neonate and infant infections
Campylobacter jujuni Enteritis, Guillian-Barre syndrome
Host silica acid taken up by pathogens
Hemophilus influenzae Respiratory infections
Hemophilus ducreyi Chancroid
Sialic acid transferred by trans-sialidase
Trypanosoma Cruzi
Chagas disease resulted in IL-1b up-regulation, controlling monocyte activation. CD33 at the cell surface is crucial to maintaining monocytes in the resting state. If there is decreased, levels of SIA in the microenvironment CD33 will induce IL-1b production by monocytes, thus participating in the delivery of alarm signals [13] .
Carynebacterium diptheraie Diphteria
CD33 is found to be expressed in 90% of Acute Myeloid Leukemia (AML) blasts [14] . Clinical data have been shown with immunoconjugates consisting of the humanized anti-CD33 antibody (gemtuzumab) and the cytotoxic drug calicheamicin (ozogamicin) as an effective anti-AML regimen. Ozogamicin (GO), the first drug conjugate approved for clinical use for anti-leukemia therapy [15] . After binding to CD33-antigens, gemtuzumab is taken into the cell via endocytosis. A new expression of CD33-antigens becomes necessary on the cellular surface of myeloid cells leads to endocytosis of gemtuzumab present, leading to efficacy in killing cells [16] .
The low expression of CD33 and the slow internalization of CD33/ antibody complexes leads to relatively limited CD33-mediated drug uptake per unit of time; consequently, for an anti-CD33 antibodydrug conjugate to be most successful, a highly potent toxin will be required [17] . Several novel CD33-targeted therapeutics that may overcome some of the limitations of earlier therapeutics are currently in preclinical and early clinical development. The low expression of CD33 and the slow internalization of CD33/antibody complexes leads to relatively limited CD33-mediated drug uptake [18] . Targeting CD33 proved to be difficult and GO withdrawn from the U.S. and European markets because of a lack of overall efficacy [19] .
We recently showed that UCB cells on ex vivo treatment with Metadichol ® a Nanoemulsion of long-chain alcohols showed enriched CD34+ cells [20] . Metadichol ® is an inverse agonist [21] of Vitamin D Receptor (VDR), a TNF-α inhibitor [22] and anti-diabetic agent as well as anti-microbial agent [23, 24] . This paper deals with Metadichol ® expression on UCB cells leading to increased CD33 expression similar to what we saw in CD34 expression. The increased expression observed with CD33 could be one possible mechanism that could explain its diverse pharmacological actions of Metadochol ® on multiple diseases [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] .
Experimental
Work was outsourced and carried out by Skandia Labs, Pvt Ltd, Bangalore India Antibody: CD33-FITC Conjugate purchased from BD Pharmingen.
Cell line: Umbilical Cord Blood (UCB) cells,
Procedure:
1. Culture 1 × 10 6 cells in a 6 well plate containing 2 ml of complete media 2. After 24 hrs of incubation, cells are treated with 1 pg, 100 pg, 1 ng, 100 ng and 1 µg in serum-free DMEM media and incubated for 72 hrs 3. After 72 hrs of treatment, cells were collected and, pelleted cells at 4000 rpm for 5 minutes at room temperature and discard the supernatant ® showed a 15 fold increase in expression of CD33+ cells (77.52%) compared to control cells (5%). The cells treated at 100 pg showed highest increase (>400 fold) in CD33++ expression (48.77%) compared to untreated control (0.11%). The reason we believe that there is less expression at higher concentration may have to do with the pH which about 4.5 and this can affect some but not all cell lines. In virus cell lines, we have noticed that it is toxic to cancer cells at higher concentrations.
Discussion
We have shown previously that Metadichol ® binds to VDR whose natural ligand is Calcitriol. We have published Metadichol's action on biomarkers implicated in various diseases [25] [26] [27] [28] . It exhibits antimicrobial activity against parasites, viruses, and bacteria. The shortest interaction path, between the two genes VDR and CD33 is shown in Figure 2 . It was generated by a web-based program ConsensusPathDB [39] . CD14 is an endogenous ligand for CD33 [40] . Calcitriol regulates CD14 in human cells. CD14 binding to CD33 leads to TLR4-mediated signaling plays an essential role in initiating the innate immune response [41] .
Gonzales, et al., [5] have shown that diabetic patients have low levels of CD33 when compared to healthy control, where as the TNF-α levels are high. This work correlates with our studies that show Metadichol ® reduces sugar levels and also TNF-α level in diabetic rats. All these downfield effects result from binding to nuclear receptor VDR (Figure 3 ).
Many pathogens incorporate SIAs into their surface glycoconjugates through various mechanisms [42] . Research supports the notion that SIA molecular mimicry can be exploited as a virulence to subvert host immune systems or to infect permissive target cells through an interaction with various Siglecs. Bacterial, fungus and viruses produce SIAs. Pathogenic microbes have evolved evolutionary mechanisms to interact with Siglecs. These pathogens displaying SIAs evade the immune system and thus dampen host immune response. SIAs are recognized and bind to CD33 related siglecs [43] and help maintain homeostasis of host innate immune response, allowing an inflammatory response that is activated upon sensing of dangerassociated molecular patterns or pathogen-associated molecular patterns [44] . Enhanced expression of CD33 thus allows it to bind to any SIAs present and those released by pathogens and thus prevent infection of the host. Metadichol ® is a food derivative and free of toxic effects [45] [46] [47] . It can be safely used alone or in combination with existing treatment protocols. 
